PDEX Stock Analysis: Pro-Dex | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 209m USD | 12M Return: 64.6% | US74265M2052 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.38M
EPS Trend: 84.0%
Qual. Beats: 1
Rev. Trend: 99.3%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pro-Dex, Inc. (NASDAQ: PDEX) is a micro-cap medical technology company that designs, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) worldwide. Its core product line includes autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers used primarily in orthopedic, thoracic, and craniomaxillofacial surgical procedures.
In addition to its medical device business, Pro-Dex generates revenue from engineering, quality, and regulatory consulting services and from the sale of rotary air motors to various industrial customers. The company serves a diverse end-user base that includes hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations.
Operating within the GICS Health Care Equipment sub-industry, Pro-Dex competes in the powered surgical instrument segment, where OEMs typically require long product qualification cycles, ISO 13485 quality system compliance, and regulatory clearances such as FDA 510(k) approvals before commercializing branded products. The company has been public since 1995 and is headquartered in Irvine, California, where it was founded in 1978.
- OEM customer concentration in orthopedic drives revenue volatility
- FDA clearances for new surgical drivers expand addressable market
- Input cost inflation pressures gross margins on medical instruments
| Net Income: 12.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 12.02 > 1.0 |
| NWC/Revenue: 52.35% < 20% (prev 49.32%; Δ 3.03% < -1%) |
| CFO/TA 0.10 > 3% & CFO 7.34m > Net Income 12.0m |
| Net Debt (10.0m) to EBITDA (19.6m): 0.51 < 3 |
| Current Ratio: 3.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.27m) vs 12m ago -2.03% < -2% |
| Gross Margin: 27.78% > 18% (prev 31.36%; Δ -3.58% > 0.5%) |
| Asset Turnover: 107.2% > 50% (prev 99.77%; Δ 7.43% > 0%) |
| Interest Coverage Ratio: 22.56 > 6 (EBIT TTM 17.4m / Interest Expense TTM 769k) |
| A: 0.52 (Total Current Assets 53.7m - Total Current Liabilities 14.6m) / Total Assets 75.0m |
| B: 0.60 (Retained Earnings 45.2m / Total Assets 75.0m) |
| C: 0.25 (EBIT TTM 17.4m / Avg Total Assets 69.6m) |
| D: 1.52 (Book Value of Equity 45.2m / Total Liabilities 29.8m) |
| Altman-Z'' = 8.65 = AAA |
| DSRI: 1.07 (Receivables 19.8m/15.9m, Revenue 74.6m/64.1m) |
| GMI: 1.13 (GM 31.36% / 27.78%) |
| AQI: 1.34 (AQ_t 0.27 / AQ_t-1 0.20) |
| SGI: 1.16 (Revenue 74.6m / 64.1m) |
| TATA: 0.06 (NI 12.0m - CFO 7.34m) / TA 75.0m) |
| Beneish M = -2.53 (Cap -4..+1) = A |
As of August 15, 2026, the stock is trading at USD 67.02 with a total of 24,163 shares traded. Over the past week, the price has changed by +2.23%, over one month by +15.04%, over three months by +14.27% and over the past year by +64.63%.
Current recommended Stop Loss: 57.90 (which is 13.6% or 2.5 ATR below the current price).
Pro-Dex has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy PDEX.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 70 | 4.4% |
P/E Trailing = 18.0606
P/E Forward = 23.5294
P/S = 2.8045
P/B = 4.6177
Revenue TTM = 74.6m USD
EBIT TTM = 17.4m USD
EBITDA TTM = 19.6m USD
Long Term Debt = 14.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.03m USD (from shortTermDebt, last quarter)
Debt = 21.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 838k
Net Debt = 10.0m USD (calculated: Debt 21.0m - CCE 11.0m)
Enterprise Value = 219.3m USD (209.3m + Debt 21.0m - CCE 11.0m)
Interest Coverage Ratio = 22.56 (Ebit TTM 17.4m / Interest Expense TTM 769k)
EV/FCF = 31.47x (Enterprise Value 219.3m / FCF TTM 6.97m)
FCF Yield = 3.18% (FCF TTM 6.97m / Enterprise Value 219.3m)
FCF Margin = 9.34% (FCF TTM 6.97m / Revenue TTM 74.6m)
Net Margin = 16.08% (Net Income TTM 12.0m / Revenue TTM 74.6m)
Gross Margin = 27.78% ((Revenue TTM 74.6m - Cost of Revenue TTM 53.9m) / Revenue TTM)
Gross Margin QoQ = 30.74% (prev 30.77%)
Tobins Q-Ratio = 2.93 (Enterprise Value 219.3m / Total Assets 75.0m)
Interest Expense / Debt = 3.66% (Interest Expense 769k / Debt 21.0m)
Taxrate = 25.41% (4.09m / 16.1m)
NOPAT = 12.9m (EBIT 17.4m * (1 - 25.41%))
Current Ratio = 3.67 (Total Current Assets 53.7m / Total Current Liabilities 14.6m)
Debt / Equity = 0.46 (Debt 21.0m / totalStockholderEquity, last quarter 45.2m)
Debt / EBITDA = 0.51 (Net Debt 10.0m / EBITDA 19.6m)
Debt / FCF = 1.44 (Net Debt 10.0m / FCF TTM 6.97m)
Total Stockholder Equity = 41.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 17.24% (Net Income 12.0m / Total Assets 75.0m)
RoE = 29.10% (Net Income TTM 12.0m / Total Stockholder Equity 41.2m)
RoCE = 31.23% (EBIT 17.4m / Capital Employed (Equity 41.2m + L.T.Debt 14.3m))
RoIC = 21.00% (NOPAT 12.9m / Invested Capital 61.6m)
WACC = 7.16% (E(209.3m)/V(230.3m) * Re(7.60%) + D(21.0m)/V(230.3m) * Rd(3.66%) * (1-Tc(0.25)))
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -83.08 | Cagr: -4.33%
[DCF] Terminal Value 75.44% ; FCFF base≈6.97m ; Y1≈7.00m ; Y5≈7.41m
[DCF] Fair Price = 32.97 (EV 115.3m - Net Debt 10.0m = Equity 105.3m / Shares 3.19m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 84.03 | EPS CAGR: 89.24% | SUE: 1.68 | # QB: 1
Revenue Correlation: 99.25 | Revenue CAGR: 21.42% | SUE: 3.25 | # QB: 3
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-06-30): EPS=2.38 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=-10.9% | GrowthRev=+14.7%
EPS next Year (2027-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+6.0%